MLYS - NASDAQ
Mineralys Therapeutics, Inc.
$25.06
-19%Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
At a Glance
Live Snapshotmlys
Total Equity
Last Annual Value
646.69M
3-Year CAGR
143%
5-Year CAGR
183%
10-Year CAGR
68%
Mineralys Therapeutics, Inc. Competitors Analysis of Total Equity
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Mineralys Therapeutics, Inc. NASDAQ:MLYS | 646.69M | 38.9% | N/A | N/A | |
 Cidara Therapeutics, Inc. NASDAQ:CDTX | 163.31M | N/A | 49.9% | 6.4% | |
 Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX | 954.27M | 35.0% | 35.8% | 37.6% | |
 Scholar Rock Holding Corporation NASDAQ:SRRK | 245.49M | 2.9% | 7.4% | N/A | |
 IDEAYA Biosciences, Inc. NASDAQ:IDYA | 1.02B | 18.1% | 27.7% | N/A | |
 Agios Pharmaceuticals, Inc. NASDAQ:AGIO | 1.19B | 13.7% | -1.6% | 12.8% | |
 Apellis Pharmaceuticals, Inc. NASDAQ:APLS | 370.15M | 23.9% | 13.3% | 31.6% | |
 Adaptive Biotechnologies Corporation NASDAQ:ADPT | 225.00M | -10.0% | -17.9% | N/A | |
 Recursion Pharmaceuticals, Inc. NASDAQ:RXRX | 1.13B | 34.6% | 15.8% | N/A | |
 Beam Therapeutics Inc. NASDAQ:BEAM | 1.24B | 8.1% | 8.4% | N/A |
Mineralys Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your MLYS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.